Catalent Pharma Solutions has signed a supply agreement with Vivus to supply Qsymia capsules, a proprietary combination phentermine and extended-release topiramate.
Catalent Modified Release Technologies president Ian Muir said Catalent is pleased to have partnered with VIVUS to develop Qsymia and look forward to a long and successful relationship.
"As a combination therapy with two active ingredients that needed to be formulated and delivered in a controlled release dosage form, Qsymia presented unique formulation and drug delivery challenges,'' Muir added.
Vivus president Peter Tam said the company has completed a long-term commercial supply agreement with Catalent to ensure the reliable on-going supply of Qsymia.
FDA has recently approved Qsymia as the first once-daily combination treatment for chronic weight management in adults who are obese or overweight with a weight-related co-morbidity.
